Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk May Use Priority Review Voucher To Speed Oral Semaglutide To Market

Executive Summary

Novo Nordisk’s chief science officer tells Scrip the readout of its PIONEER 6 trial on oral semaglutide came earlier than originally thought, allowing for an FDA filing in first-half 2019, and that use of a priority review voucher is a clear option that could speed up the process.  

You may also be interested in...



Novo Nordisk Using Priority Review Voucher To Propel Oral Semaglutide To Market

Danish diabetes fighter will file oral semaglutide with FDA within months using a priority review voucher to reduce the time for expected approval to six months.

Q4 Pharma Earnings Preview: Roche, Celgene, Novo Nordisk, Merck, Gilead

Roche will highlight newer drugs as cancer blockbusters feel biosimilar pressure, while Celgene will talk to investors about its pending acquisition by Bristol. Novo Nordisk has faced concerns about generic and branded competition not to mention price pressures, but its longer-term outlook is sound; Merck's Keytruda tops investors' focus; Gilead looks ahead to new CEO O'Day.

EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

New data from Novo Nordisk supporting its GLP-1 agonist will fortify the firm's new drug applications, strengthen its position in price negotiations and boost its chances of reimbursement.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel